Anthropic Invests $400M in AI Startup Coefficient Bio
Le brief IA que les pros lisent chaque soir
Les 7 actus IA du jour, décryptées en 5 min. Gratuit.
Inclus dès l'inscription : notre sélection des meilleurs guides & comparatifs IA.
Choisis ton rythme
Gratuit · Pas de spam · Désabonnement en 1 clic
Anthropic recently acquired Coefficient Bio, a young startup specializing in artificial intelligence applied to the pharmaceutical sector, for approximately $400 million in stock. This transaction, reported by Newcomer and The Information, highlights the growing interest in AI within the healthcare field.
Founded just eight months ago, Coefficient Bio stands out with its small team of fewer than ten employees. The startup has developed an innovative platform that uses AI to optimize pharmaceutical processes such as drug research planning and the identification of new therapeutic opportunities.
Anthropic's acquisition appears to be driven by the desire to harness the talent of Coefficient Bio. The startup's team will join Anthropic's Health and Life Sciences division, led by Eric Kauderer-Abrams, to bolster the company's efforts in this area.
The venture capital firm Dimension, which owned about half of Coefficient Bio, achieved an impressive return on investment of 38,513%. Neither Anthropic nor Dimension wished to comment on this transaction.
This acquisition occurs against a backdrop of major pharmaceutical companies ramping up their investments in AI. For example, Eli Lilly recently struck a billion-dollar deal with Insilico Medicine, an AI-based drug developer. Meanwhile, Anthropic is already collaborating with giants like Sanofi, Novo Nordisk, and AbbVie, while Google DeepMind has launched its own initiative in the field of AI medicine.
Brief IA — L'actualité IA en français
L'essentiel de l'actualité de l'intelligence artificielle, décrypté et expliqué chaque jour.